Myriad Genetics, Inc.’s filing revealed that its Chief Financial Officer Riggsbee Richard Bryan unloaded Company’s shares for reported $0.57 million on Dec 01 ’23. In the deal valued at $19.09 per share,30,000 shares were sold. As a result of this transaction, Riggsbee Richard Bryan now holds 291,812 shares worth roughly $6.09 million.
Then, Riggsbee Richard Bryan sold 30,000 shares, generating $470,622 in total proceeds. Upon selling the shares at $15.69, the Chief Financial Officer now owns 321,812 shares.
Before that, SPIEGELMAN DANIEL K sold 8,638 shares. Myriad Genetics, Inc. shares valued at $198,760 were divested by the Director at a price of $23.01 per share. As a result of the transaction, SPIEGELMAN DANIEL K now holds 40,493 shares, worth roughly $0.85 million.
A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in mid December with a ‘”an Equal weight”‘ rating. Guggenheim began covering MYGN with “Buy” recommendation on December 14, 2023. Wolfe Research started covering the stock on December 13, 2023. It rated MYGN as “an Outperform”.
Price Performance Review of MYGN
On Tuesday, Myriad Genetics, Inc. [NASDAQ:MYGN] saw its stock jump 2.65% to $20.88. Over the last five days, the stock has gained 4.40%. Myriad Genetics, Inc. shares have risen nearly 9.09% since the year began. Nevertheless, the stocks have fallen -10.50% over the past one year. While a 52-week high of $24.21 was reached on 02/28/24, a 52-week low of $13.82 was recorded on 01/08/24. SMA at 50 days reached $21.97, while 200 days put it at $19.40. A total of 0.52 million shares were traded, compared to the trading of 0.53 million shares in the previous session.
Levels Of Support And Resistance For MYGN Stock
The 24-hour chart illustrates a support level at 20.48, which if violated will result in even more drops to 20.08. On the upside, there is a resistance level at 21.17. A further resistance level may holdings at 21.46. The Relative Strength Index (RSI) on the 14-day chart is 45.17, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.68, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 58.41%. Stochastics %K at 29.31% indicates the stock is a holding.
How much short interest is there in Myriad Genetics, Inc.?
A steep rise in short interest was recorded in Myriad Genetics, Inc. stocks on Mar 28, 2024, growing by 1.67 million shares to a total of 5.67 million shares. Yahoo Finance data shows the prior-month short interest on Feb 29, 2024 was 4.0 million shares. There was a rise of 29.45%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 8.71% of the overall stock float, the days-to-cover ratio (short ratio) rose to 7.73.
